Sun Pharmaceutical Industries sharesgained
after the US FDA has granted its subsidiary final approval for its
Abbreviated New Drug Application (ANDA) to market a generic version
of Temodar, Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180
mg and 250 mg.
Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and
250 mg are therapeutic equivalents of Merck Sharp & Dohme
Corporation's Temodar Capsules.
Shares of the company are trading at Rs
622.30, up Rs 7.6, or 1.24% at the Bombay Stock Exchange (BSE) on
Friday at 10:07 a.m.The scrip has touched an intra-day high of Rs
626.25 and low of Rs 619.10. The total volume of shares traded at
the BSE is 71,518.In the earlier session, the shares climbed 0.6%,
or Rs 3.65, at Rs 614.70.Currently, the stock is trading down 4.26%
from its 52-week high of Rs 650.00 and above 61.57% over the
52-week low of Rs 385.15.